Abstract
Using in vitro drug sensitivity data coupled with Affymetrix microarray data, we developed gene expression signatures that predict sensitivity to individual chemotherapeutic drugs. Each signature was validated with response data from an independent set of cell line studies. We further show that many of these signatures can accurately predict clinical response in individuals treated with these drugs. Notably, signatures developed to predict response to individual agents, when combined, could also predict response to multidrug regimens. Finally, we integrated the chemotherapy response signatures with signatures of oncogenic pathway deregulation to identify new therapeutic strategies that make use of all available drugs. The development of gene expression profiles that can predict response to commonly used cytotoxic agents provides opportunities to better use these drugs, including using them in combination with existing targeted therapies.
NOTE: In the version of this article initially published online, the affiliations of some authors were incorrectly listed. R.S. and J.C. should be affiliation 4, and the correct address for this affiliation should be Division of Gynecologic Surgical Oncology, H. Lee Moffitt Cancer Center & Research Institute, University of South Florida, 12902 Magnolia Drive, Tampa, Florida 33612, USA. Also, "Center for Applied Genomics and Technology" should be omitted from affiliation 1. The error has been corrected for all versions of the article.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Change history
27 October 2006
In the version of this article initially published online, the affiliations of some authors were incorrectly listed. R.S. and J.C. should be affiliation 4, and the correct address for this affiliation should be Division of Gynecologic Surgical Oncology, H. Lee Moffitt Cancer Center & Research Institute, University of South Florida, 12902 Magnolia Drive, Tampa, Florida 33612, USA. Also, "Center for Applied Genomics and Technology" should be omitted from affiliation 1. The error has been corrected for all versions of the article.
21 July 2008
Nature Medicine 11, 1294-1300 (2006); published online 22 October 2006; corrected online 27 October 2006 and corrected after print 21 July 2008. In the version of this article initially published, of the 122 samples assayed for sensitivity to daunorubicin for which the authors applied a predictor of adriamycin sensitivity (Fig. 2c), 27 samples were replicated owing to the fact that the same samples were included in several separate series files in the Gene Expression Omnibus generated in 2004 and 2005, which were the source of the data provided for the study. The authors have reanalyzed the prediction of adriamycin sensitivity using only the 95 unique samples and find a revised accuracy of 74%. Additionally, the authors have added two more accession numbers (GSE2351 and GSE649) to more clearly identify the sources of the samples. The errors have been corrected in the HTML and PDF versions of the article.
07 January 2011
This Article has been retracted. See the full retraction notice for details.
References
Herbst, R.S. et al. Clinical cancer advances 2005: major research advances in cancer treatment, prevention, and screening—a report from the American Society of Clinical Oncology. J. Clin. Oncol. 24, 190–205 (2006).
Breathnach, O.S. et al. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J. Clin. Oncol. 19, 1734–1742 (2001).
Blagosklonny, M.V. Why therapeutic response may not prolong the life of a cancer patient: selection for oncogenic resistance. Cell Cycle 4, 1693–1698 (2005).
Staunton, J.E. et al. Chemosensitivity prediction by transcriptional profiling. Proc. Natl. Acad. Sci. USA 98, 10787–10792 (2001).
Chang, J.C. et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362, 362–369 (2003).
Emi, M., Kim, R., Tanabe, K., Uchida, Y. & Toge, T. Targeted therapy against Bcl-2-related proteins in breast cancer cells. Breast Cancer Res. 7, R940–R952 (2005).
Takahashi, T. et al. Cyclin A-associated kinase activity is needed for paclitaxel sensitivity. Mol. Cancer Ther. 4, 1039–1046 (2005).
Modi, S. et al. Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer. Cancer Invest. 23, 483–487 (2005).
Langer, R. et al. Association of pretherapeutic expression of chemotherapy-related genes with response to neoadjuvant chemotherapy in Barrett carcinoma. Clin. Cancer Res. 11, 7462–7469 (2005).
Gyorffy, B. et al. Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int. J. Cancer 118, 1699–1712 (2005).
Rouzier, R. et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin. Cancer Res. 11, 5678–5685 (2005).
Rouzier, R. et al. Microtubule-associated protein tau: a marker of paclitaxel sensitivity on breast cancer. Proc. Natl. Acad. Sci. USA 102, 8315–8320 (2005).
DeVita, V.T., Hellman, S. & Rosenberg, S.A. Cancer: Principles and Practice of Oncology (Lippincott-Raven, Philadelphia, 2005).
Broxterman, H.J. & Georgopapadakou, N.H. Anticancer therapeutics: “addictive” targets, multi-targeted drugs, new drug combinations. Drug Resist. Updat. 8, 183–197 (2005).
Minna, J.D., Gazdar, A.F., Sprang, S.R. & Herz, J. Cancer: a bull's eye for targeted lung cancer therapy. Science 304, 1458–1461 (2004).
Bild, A. et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439, 353–357 (2006).
Vogel, C.L. et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20, 719–726 (2002).
Lugthart, S. et al. Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia. Cancer Cell 7, 375–386 (2005).
Holleman, A. et al. Gene expression patterns in drug resistant acute lymphoblastic leukemia cells and response to treatment. N. Engl. J. Med. 351, 533–542 (2004).
Sargent, D.J., Conley, B.A., Allegra, C. & Collette, L. Clinical trial designs for predictive marker validation in cancer treatment trials. J. Clin. Oncol. 23, 2020–2027 (2005).
Pittman, J., Huang, E., Wang, Q., Nevins, J.R. & West, M. Bayesian analysis of binary prediction tree models for retrospectively sampled outcomes. Biostatistics 5, 587–601 (2004).
Miller, A.B., Hoogstraten, B., Staquet, M. & Winkler, A. Reporting results of cancer treatment. Cancer 47, 207–214 (1981).
West, M. et al. Predicting the clinical status of human breast cancer by using gene expression profiles. Proc. Natl. Acad. Sci. USA 98, 11462–11467 (2001).
Ihaka, R. & Gentleman, R. A language for data analysis and graphics. J. Comput. Graph. Stat. 5, 299–314 (1996).
Eisen, M.B., Spellman, P.T., Brown, P.O. & Botstein, D. Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. USA 95, 14863–14868 (1998).
Acknowledgements
The authors would like to acknowledge and thank L. Pusztai for providing us with the clinical and expression data on the samples studied from the M.D. Anderson Cancer Center. Funding for this work was supplied in part by research grants from the US National Institutes of Health (NCI-U54 CA112952-02 (J.R.N.) and R01CA106520 (J.R.N.)). A.P. is an American Association for Cancer Research Translational Research Grant awardee, J.L. receives research support from Glaxo-Smith-Kline and Sanofi-Aventis Pharmaceuticals and Orthobiotech, and P.F. is a Damon Runyon Cancer Research Investigator. Additional sources of funding included the Ovarian Cancer Research Fund and the Hearing the Ovarian Cancer Whisper Jacquie Liggett Fellowship.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J.L. reports receiving research support from Glaxo-Smith-Kline, Sanofi-Aventis and Orthobiotech. There are no other competing financial interests.
Supplementary information
Supplementary Fig. 1
A patient-derived docetaxel gene expression signature predicts response to docetaxel in cancer cell lines (PDF 227 kb)
Supplementary Fig. 2
Development of gene expression signatures that predict sensitivity to a panel of commonly used chemotherapeutic drugs (PDF 379 kb)
Supplementary Fig. 3
Specificity of chemotherapy response predictors (PDF 184 kb)
Supplementary Fig. 4
Relationships in predicted probability of response to chemotherapies in breast (Panel A), lung (Panel B) and ovarian cancer (Panel C) (PDF 279 kb)
Supplementary Fig. 5
Integrating prediction of oncogenic pathway deregulation with chemotherapeutic sensitivity (PDF 370 kb)
Supplementary Table 1
The genes constituting the individual chemosensitivity predictors developed on the NCI-60 cell line panel and the genes constituting the PI3 kinase pathway predictor (PDF 452 kb)
Supplementary Table 2
A summary of the chemotherapy response predictors: validations in cell line and patient data sets (PDF 49 kb)
Supplementary Table 3
An enrichment analysis showing that a genomic-guided response prediction increases the probability of a clinical response in the different data sets studied; a comparison of this data to previously reported predictors of response (PDF 50 kb)
Rights and permissions
About this article
Cite this article
Potti, A., Dressman, H., Bild, A. et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med 12, 1294–1300 (2006). https://doi.org/10.1038/nm1491
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm1491
This article is cited by
-
Teaching reproducible research for medical students and postgraduate pharmaceutical scientists
BMC Research Notes (2021)
-
Upregulation of GPNCA is associated with poor prognosis through enhancement of tumor growth via regulating GSK3B
Scientific Reports (2020)
-
Building a Personalized Cancer Treatment System
Journal of Medical Systems (2017)
-
Intra- and interspecies gene expression models for predicting drug response in canine osteosarcoma
BMC Bioinformatics (2016)
-
Optimization of drug combinations using Feedback System Control
Nature Protocols (2016)